CTMX Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 46.2% compared to CytomX Therapeutics's net margin of 50.24%. CytomX Therapeutics's return on equity of -- beat Johnson & Johnson's return on equity of 30.18%.

CytomX Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 148.87%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 11.1%. Given that CytomX Therapeutics has higher upside potential than Johnson & Johnson, analysts believe CytomX Therapeutics is more attractive than Johnson & Johnson.

CytomX Therapeutics has a beta of 2.115, which suggesting that the stock is 111.484% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.3% to investors and pays a quarterly dividend of $1.30 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytomX Therapeutics quarterly revenues are $50.9M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. CytomX Therapeutics's net income of $23.5M is lower than Johnson & Johnson's net income of $11B. Notably, CytomX Therapeutics's price-to-earnings ratio is 4.51x while Johnson & Johnson's PE ratio is 16.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 1.28x versus 4.14x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 46.2% compared to CytomX Therapeutics's net margin of 21.68%. CytomX Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

CytomX Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 148.87%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 20.15%. Given that CytomX Therapeutics has higher upside potential than Eli Lilly and, analysts believe CytomX Therapeutics is more attractive than Eli Lilly and.

CytomX Therapeutics has a beta of 2.115, which suggesting that the stock is 111.484% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytomX Therapeutics quarterly revenues are $50.9M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. CytomX Therapeutics's net income of $23.5M is lower than Eli Lilly and's net income of $2.8B. Notably, CytomX Therapeutics's price-to-earnings ratio is 4.51x while Eli Lilly and's PE ratio is 64.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 1.28x versus 14.60x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 46.2% compared to CytomX Therapeutics's net margin of 32.71%. CytomX Therapeutics's return on equity of -- beat Merck &'s return on equity of 39.02%.

CytomX Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 148.87%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 27.76%. Given that CytomX Therapeutics has higher upside potential than Merck &, analysts believe CytomX Therapeutics is more attractive than Merck &.

CytomX Therapeutics has a beta of 2.115, which suggesting that the stock is 111.484% more volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.02% to investors and pays a quarterly dividend of $0.81 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytomX Therapeutics quarterly revenues are $50.9M, which are smaller than Merck & quarterly revenues of $15.5B. CytomX Therapeutics's net income of $23.5M is lower than Merck &'s net income of $5.1B. Notably, CytomX Therapeutics's price-to-earnings ratio is 4.51x while Merck &'s PE ratio is 11.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 1.28x versus 3.16x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 46.2% compared to CytomX Therapeutics's net margin of -60.08%. CytomX Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

CytomX Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 148.87%. On the other hand Sarepta Therapeutics has an analysts' consensus of $48.04 which suggests that it could grow by 175.14%. Given that Sarepta Therapeutics has higher upside potential than CytomX Therapeutics, analysts believe Sarepta Therapeutics is more attractive than CytomX Therapeutics.

CytomX Therapeutics has a beta of 2.115, which suggesting that the stock is 111.484% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $50.9M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. CytomX Therapeutics's net income of $23.5M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, CytomX Therapeutics's price-to-earnings ratio is 4.51x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 1.28x versus 0.87x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.